As CEO of the Samsung Bioepis joint venture between Samsung BioLogics and Biogen, Christopher Hansung Ko oversees a major player in the global biosimilars arena that can boast substantial interests and experience in the US market, as well as a wealth of experience in Europe and a foot in the door of major Asian and Latin American markets like China and Brazil.
In the first part of an exclusive interview with Generics Bulletin, Ko highlighted the need for stakeholders to adopt a patient and cautious approach
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?